Thyrocare to sell Nueclear Healthcare for Rs 141.4 Cr, focus on pathology
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Thyrocare board approved sale of its 100 percent stake in subsidiary Nueclear Healthcare (NHL) to Trovera Healthcare for about Rs 141.4 crore. NHL runs a radiology business with Rs 44.62 Cr turnover (5.4 percent of consolidated). Consideration: 42,500 CCPS of Trovera worth Rs 59.5 Cr plus Rs 81.9 Cr cash. Thyrocare will exit radiology to focus on its core pathology business. Also buying back lab properties in Gurugram and Hyderabad from NHL for Rs 20.59 Cr. Transaction needs shareholder approval, expected by November 30, 2026.
Strategic exit from radiology to sharpen focus on core pathology. Net cash inflow around Rs 81.9 Cr plus a small stake of about 4.5 percent in Trovera via CCPS.